Laird Norton Wetherby Wealth Management’s Decoy Therapeutics DCOY Stock Holding History

Laird Norton Wetherby Wealth Management’s Portfolio DCOY Stock Details DCOY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1	Closed	-$8K	–	952
2022 Q3	$8K	Hold	1	–	–	﹤0.01%	882
2022 Q2	$8K	Hold	1	–	–	﹤0.01%	903
2022 Q1	$16K	Hold	1	–	–	﹤0.01%	927
2021 Q4	$20K	Hold	1	–	–	﹤0.01%	928
2021 Q3	$41K	Hold	1	–	–	﹤0.01%	927
2021 Q2	$42K	Hold	1	–	–	﹤0.01%	926
2021 Q1	$59K	Hold	1	–	–	﹤0.01%	779
2020 Q4	$36K	Hold	1	–	–	﹤0.01%	902
2020 Q3	$34K	Hold	1	–	–	﹤0.01%	718
2020 Q2	$52K	Hold	1	–	–	﹤0.01%	708
2020 Q1	$27K	Hold	1	–	–	﹤0.01%	677
2019 Q4	$150K	Hold	1	–	–	0.01%	682
2019 Q3	$271K	Buy	+1	New	+$341K	0.03%	577

Other funds holding DCOY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Laird Norton Wetherby Wealth Management's DCOY Position: Q4 2022 in Review

Laird Norton Wetherby Wealth Management sold out of Decoy Therapeutics (DCOY) in Q4 2022, closing a stake of 1 share — an estimated $8K sold.

Laird Norton Wetherby Wealth Management first reported a position in DCOY in Q3 2019 and held it in 13 quarters. The position peaked at $271K in Q3 2019. 4 funds tracked by Wall St. Rank hold DCOY as of Q4 2022.

Laird Norton Wetherby Wealth Management reported no remaining Decoy Therapeutics position as of Q4 2022 after selling out during the quarter.
Laird Norton Wetherby Wealth Management sold 1 Decoy Therapeutics share in Q4 2022, an estimated $8K.
Laird Norton Wetherby Wealth Management first reported a position in Decoy Therapeutics in Q3 2019 and held it in 13 quarters.
Laird Norton Wetherby Wealth Management's Decoy Therapeutics position peaked at $271K in Q3 2019.
4 funds tracked by Wall St. Rank held Decoy Therapeutics as of Q4 2022.

Based on Laird Norton Wetherby Wealth Management's 13F filing for Q4 2022, filed 14 Feb 2023.